Literature DB >> 35309729

Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.

Beatriz Álvarez-Abril1,2, Elena García-Martínez2,3,4, Lorenzo Galluzzi1,5,6.   

Abstract

Epithelial ovarian carcinoma (EOC) is virtually insensitive to immune checkpoint inhibitors (ICIs). Recent findings from an innovative mouse model of EOC demonstrate that senescence induction underlies the increased sensitivity of homologous recombination-defective EOCs to platinum-based chemotherapy as it initiates tumor infiltration by immune effector cells coupled to restored sensitivity to ICIs.
© 2022 Taylor & Francis Group, LLC.

Entities:  

Keywords:  BRCA1/2; CGAS; GEMM; NK cells; PD-1; senescence-associated secretory phenotype

Mesh：

Substances：

Year:  2022        PMID： 35309729      PMCID： PMC8932912          DOI： 10.1080/2162402X.2022.2052411

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  The hallmarks of successful anticancer immunotherapy.

Authors:  Lorenzo Galluzzi; Timothy A Chan; Guido Kroemer; Jedd D Wolchok; Alejandro López-Soto
Journal:  Sci Transl Med       Date:  2018-09-19       Impact factor: 17.956

Review 2.  Cellular Senescence: Defining a Path Forward.

Authors:  Vassilis Gorgoulis; Peter D Adams; Andrea Alimonti; Dorothy C Bennett; Oliver Bischof; Cleo Bishop; Judith Campisi; Manuel Collado; Konstantinos Evangelou; Gerardo Ferbeyre; Jesús Gil; Eiji Hara; Valery Krizhanovsky; Diana Jurk; Andrea B Maier; Masashi Narita; Laura Niedernhofer; João F Passos; Paul D Robbins; Clemens A Schmitt; John Sedivy; Konstantinos Vougas; Thomas von Zglinicki; Daohong Zhou; Manuel Serrano; Marco Demaria
Journal:  Cell       Date:  2019-10-31       Impact factor: 41.582

Review 3.  Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.

Authors:  Jitka Fucikova; Lenka Palova-Jelinkova; Vanessa Klapp; Peter Holicek; Tereza Lanickova; Lenka Kasikova; Jana Drozenova; David Cibula; Beatriz Álvarez-Abril; Elena García-Martínez; Radek Spisek; Lorenzo Galluzzi
Journal:  Trends Cancer       Date:  2022-02-16

4.  Senescence Inflames the Pancreatic Tumor Microenvironment.

Authors:  Giulia Petroni; Lorenzo Galluzzi
Journal:  Cell Rep Med       Date:  2020-05-19

5.  Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy.

Authors:  Takahiro Yamazaki; Alexander Kirchmair; Ai Sato; Aitziber Buqué; Marissa Rybstein; Giulia Petroni; Norma Bloy; Francesca Finotello; Lena Stafford; Esther Navarro Manzano; Francisco Ayala de la Peña; Elena García-Martínez; Silvia C Formenti; Zlatko Trajanoski; Lorenzo Galluzzi
Journal:  Nat Immunol       Date:  2020-08-03       Impact factor: 25.606

6.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.

Authors:  Kyle C Strickland; Brooke E Howitt; Sachet A Shukla; Scott Rodig; Lauren L Ritterhouse; Joyce F Liu; Judy E Garber; Dipanjan Chowdhury; Catherine J Wu; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos
Journal:  Oncotarget       Date:  2016-03-22

Review 7.  High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.

Authors:  Michael-Antony Lisio; Lili Fu; Alicia Goyeneche; Zu-Hua Gao; Carlos Telleria
Journal:  Int J Mol Sci       Date:  2019-02-22       Impact factor: 5.923

8.  PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.

Authors:  Liya Ding; Hye-Jung Kim; Qiwei Wang; Michael Kearns; Tao Jiang; Carolynn E Ohlson; Ben B Li; Shaozhen Xie; Joyce F Liu; Elizabeth H Stover; Brooke E Howitt; Roderick T Bronson; Suzan Lazo; Thomas M Roberts; Gordon J Freeman; Panagiotis A Konstantinopoulos; Ursula A Matulonis; Jean J Zhao
Journal:  Cell Rep       Date:  2018-12-11       Impact factor: 9.423

9.  Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.

Authors:  Stella V Paffenholz; Camilla Salvagno; Yu-Jui Ho; Matthew Limjoco; Timour Baslan; Sha Tian; Amanda Kulick; Elisa de Stanchina; John E Wilkinson; Francisco M Barriga; Dmitriy Zamarin; Juan R Cubillos-Ruiz; Josef Leibold; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-01       Impact factor: 11.205

10.  Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of In Vivo Fallopian Tube Electroporation and CRISPR-Cas9-Mediated Genome Editing.

Authors:  Katie Teng; Matthew J Ford; Keerthana Harwalkar; YuQi Li; Alain S Pacis; David Farnell; Nobuko Yamanaka; Yu-Chang Wang; Dunarel Badescu; Tuyet Nhung Ton Nu; Jiannis Ragoussis; David G Huntsman; Jocelyne Arseneau; Yojiro Yamanaka
Journal:  Cancer Res       Date:  2021-07-23       Impact factor: 12.701
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.